We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ALS Guidance Embraces Regulatory Flexibility to Speed Treatments
ALS Guidance Embraces Regulatory Flexibility to Speed Treatments
Senior FDA officials promised “flexibility” to help address the unmet medical need as the agency released final guidance on Monday for sponsors of treatments for amyotrophic lateral sclerosis (ALS) — Lou Gehrig’s disease.